Reweighed Charlson comorbidity index more accurate in men with prostate cancer

Article

A reweighed Charlson comorbidity index (CCI) based on prostate cancer-specific data and long-term follow-up predicts long-term, other-cause mortality in prostate cancer patients better than the original CCI.

Key Points

Washington-A reweighed Charlson comorbidity index (CCI) based on prostate cancer-specific data and long-term follow-up predicts long-term, other-cause mortality in prostate cancer patients better than the original CCI, according to UCLA researchers.

Based on its performance, the revised CCI may be useful for counseling men about management of early-stage prostate cancer, said first author Timothy Daskivich, MD, a urology resident at UCLA's David Geffen School of Medicine working with Mark S. Litwin, MD, MPH, and colleagues.

Recent Videos
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
Tony Abraham, DO, MPA, a nuclear radiologist
Kelly L. Stratton, MD, FACS, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
DNA | Image Credit: © BillionPhotos.com - stock.adobe.com
Kyrollis Attalla, MD, an expert on prostate cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.